Company Filing History:
Years Active: 2022
Title: Jens Pahl: Innovator in Immunotherapy
Introduction
Jens Pahl is a notable inventor based in Dossenheim, Germany. He has made significant contributions to the field of immunotherapy, particularly through his innovative patent related to anti-CD16A antibodies. His work is pivotal in advancing treatments that harness the power of the immune system.
Latest Patents
Jens Pahl holds a patent for a "Combination of an anti-CD16A antibody with a cytokine." This invention pertains to an anti-CD16A antigen binding protein designed for use in NK cell-based immunotherapy. The unique aspect of this invention is that the anti-CD16A antigen binding protein is to be administered intermittently and in combination with a cytokine. In certain embodiments, the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody. This innovative approach has the potential to enhance the efficacy of immunotherapy treatments.
Career Highlights
Jens Pahl is associated with Affimed GmbH, a company that focuses on developing immunotherapies for cancer treatment. His role at Affimed has allowed him to work on groundbreaking research and development projects that aim to improve patient outcomes through innovative therapies.
Collaborations
Jens collaborates with esteemed colleagues such as Joachim Koch and Martin Treder. Their combined expertise contributes to the advancement of immunotherapy and the development of novel treatment strategies.
Conclusion
Jens Pahl's contributions to the field of immunotherapy through his patent and work at Affimed GmbH highlight his role as an influential inventor. His innovative approaches are paving the way for new treatments that could significantly impact cancer therapy.